$7.00
-0.10(-1.41%)
Mkt Cap $513M
$0.25
$7.17
52-Week Range
At a Glance
AI-generatedRelmada Therapeutics, Inc.
8-K
Relmada Therapeutics reported audited financial results for the full year and fourth quarter ended December 31, 2025, with a full year net loss of $57.4 million and provided a corporate update including positive 12-month Phase 2 data for NDV-01 showing 95% complete response rate at any time and 76% at 12 months in high-risk NMIBC, a $160 million PIPE financing, and plans to initiate Phase 3 RESCUE program mid-2026.$513M
Market Cap
—
Revenue
-$62M
Net Income
Employees17
Fundamentals
How The Business Makes Money
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001553643
ISINUS75955J4022
CUSIP75955J402
Phone786 629 1376
Address2222 Ponce de Leon Boulevard, Coral Gables, FL, 33134, US
SEC EDGAR